Ionis Pharmaceuticals, Inc.
IONS
Ранг среди акций
#2665
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Цена акции
$42.95
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$7.14B
Изменение (1 день)
-2.65%
Изменение (1 год)
-41.23%
Страна
US
Торговля Ionis Pharmaceuticals, Inc. (IONS)
Категория
Healthcare
Операционная маржа для Ionis Pharmaceuticals, Inc. (IONS)
Операционная маржа на October 2026 TTM: -68.09%
Согласно последним финансовым отчетам и цене акций Ionis Pharmaceuticals, Inc., текущая операционная маржа (TTM) составляет -68.09%. В конце 2023 она составила -44.91%.
История операционной маржи Ionis Pharmaceuticals, Inc. с 2000 по 2026
Операционная маржа на конец каждого года
| Год | Операционная маржа | Изменить |
|---|---|---|
| 2026 (TTM) | -68.09% | 1.07% |
| 2024 | -67.37% | 50.01% |
| 2023 | -44.91% | -35.86% |
| 2022 | -70.02% | 1,777.21% |
| 2021 | -3.73% | -84.19% |
| 2020 | -23.59% | -172.38% |
| 2019 | 32.59% | -418.57% |
| 2018 | -10.23% | -311.80% |
| 2017 | 4.83% | -136.15% |
| 2016 | -13.36% | -49.96% |
| 2015 | -26.70% | 19.78% |
| 2014 | -22.29% | -36.46% |
| 2013 | -35.08% | -48.06% |
| 2012 | -67.54% | -5.88% |
| 2011 | -71.76% | 60.97% |
| 2010 | -44.58% | 96.82% |
| 2009 | -22.65% | 85.96% |
| 2008 | -12.18% | -78.23% |
| 2007 | -55.94% | -79.85% |
| 2006 | -277.67% | 94.88% |
| 2005 | -142.48% | -48.47% |
| 2004 | -276.49% | 75.00% |
| 2003 | -157.99% | 149.31% |
| 2002 | -63.37% | -26.77% |
| 2001 | -86.54% | 11.21% |
| 2000 | -77.82% | 0.00% |
Операционная маржа для аналогичных компаний или конкурентов
| Компания | Операционная маржа | Разница в операционной марже | Страна |
|---|---|---|---|
| 38.59% | -100.57% |
US
|
|
| -149.01% | -97.81% |
US
|
|
| 25.57% | -100.38% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.42% |
NL
|
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.